Key result
Severe dynamic LVOT obstruction predicts ~87% higher risk of adverse clinical outcomes in HCM.
Why the study?
Although LVOT obstruction influences functional capacity and clinical outcomes in HCM, the clinical relevance of varying obstruction severity remains debated.
Does severe LVOT obstruction (≥80 mmHg) predict worse exercise performance and long-term prognosis in patients with hypertrophic cardiomyopathy?
Population
388 HCM patients undergoing TTE-CPET
Comparison
Peak LVOT gradient <30 mmHg vs 30-49 mmHg vs 50-79 mmHg vs >=80 mmHg
Design
Retrospective cohort study
Follow-up
Median follow-up of 7.4 years
Authors
Loading...
May identify high-risk HCM patients for closer monitoring; leaves open whether gradient-targeted intervention improves outcomes.
Cohort (n=388)
Does severe LVOT obstruction (≥80 mmHg) predict worse exercise performance and long-term prognosis in patients with hypertrophic cardiomyopathy?
Hazard Ratio: 1.87
Absolute Event Rate: 50% vs 31.6%
p-value: p=0.009
Severe dynamic LVOT obstruction (≥80 mmHg) identifies a high-risk subgroup of HCM patients with impaired exercise capacity and worse long-term prognosis, highlighting the value of TTE-CPET for risk stratification.
Mistrulli et al. (2026) conducted a cohort in Hypertrophic cardiomyopathy (n=388). Severe dynamic LVOT obstruction (peak gradient ≥80 mmHg) vs. Non-severe LVOT obstruction (<80 mmHg) was evaluated on Composite of NYHA class worsening, heart failure hospitalization, new-onset atrial fibrillation, or progression to end-stage HCM (HR 1.87, p=0.009). Severe dynamic LVOT obstruction (≥80 mmHg) independently predicted a higher risk of adverse clinical outcomes in patients with hypertrophic cardiomyopathy (50.0% vs 31.6%; HR 1.87, p=0.009).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: